0001140361-24-010584.txt : 20240301 0001140361-24-010584.hdr.sgml : 20240301 20240301060158 ACCESSION NUMBER: 0001140361-24-010584 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240301 ITEM INFORMATION: Other Events FILED AS OF DATE: 20240301 DATE AS OF CHANGE: 20240301 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Karuna Therapeutics, Inc. CENTRAL INDEX KEY: 0001771917 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 270605902 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38958 FILM NUMBER: 24706710 BUSINESS ADDRESS: STREET 1: 99 HIGH STREET STREET 2: 26TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 857-449-2244 MAIL ADDRESS: STREET 1: 99 HIGH STREET STREET 2: 26TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 8-K 1 ef20022937_8k.htm 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549


FORM 8-K


CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): March 1, 2024

Karuna Therapeutics, Inc.
(Exact name of Registrant as Specified in Its Charter)


Delaware
001-38958
27-0605902
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)

99 High Street, Floor 26
 
Boston, Massachusetts
02110
(Address of Principal Executive Offices)
(Zip Code)
 
Registrant’s Telephone Number, Including Area Code: 857 449-2244
 
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:

Title of each class
  
Trading
Symbol(s)
  
Name of each exchange
on which registered
Common stock, par value $0.0001
  
KRTX
  
Nasdaq Global Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01
Other Events.
 
On December 22, 2023, Karuna Therapeutics, Inc., a Delaware corporation (“Karuna”), Bristol-Myers Squibb Company, a Delaware corporation (“Bristol-Myers Squibb”) and Miramar Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Bristol-Myers Squibb (“Merger Sub”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which, on the terms and subject to the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Karuna (the “merger”), with Karuna continuing as the surviving corporation in the merger as a wholly owned subsidiary of Bristol-Myers Squibb.
 
On February 5, 2024, Karuna filed a definitive proxy statement with the Securities and Exchange Commission (the “SEC”) relating to the special meeting of its stockholders to be held on March 12, 2024 (the “Special Meeting”) to consider and vote on various proposals necessary to approve the Merger Agreement (the “Proxy Statement”).
 
Following the filing of the Proxy Statement, a complaint was filed by a Karuna stockholder in the United States District Court for the District of Delaware seeking to enjoin the proposed merger with Bristol-Myers Squibb (the “Complaint”).  The Complaint is captioned Jenkins v. Karuna Therapeutics, Inc., et al. (No. 24-cv-00197) and names as defendants Karuna and the members of Karuna’s board of directors.  The Complaint asserts claims under the federal securities laws and alleges that the Proxy Statement was materially incomplete and misleading.  The Complaint seeks, among other relief, injunctive relief to prevent consummation of the transactions contemplated by the Merger Agreement until the alleged disclosure violations are cured, potential rescissory damages in the event the proposed merger is consummated, as well as attorneys’ fees and costs.
 
Solely to avoid the costs, burden, nuisance and uncertainties inherent in litigation and to allow the Karuna shareholders to vote on the merger at the Special Meeting, without admitting any liability or wrongdoing, Karuna hereby supplements the disclosures contained in the Proxy Statement (the “Supplemental Disclosures”). The Supplemental Disclosures are set forth below and should be read in conjunction with the Proxy Statement.
 
Karuna vigorously denies that the Proxy Statement is deficient in any respect and that the Supplemental Disclosures are material or required. Karuna believes that the Complaint is without merit and that no further disclosure is required to supplement the Proxy Statement under applicable laws. Nothing in this Current Report on Form 8-K will be deemed an admission of the legal necessity or materiality under any applicable laws for any of the disclosures set forth herein.
 
SUPPLEMENT TO PROXY STATEMENT
 
Karuna hereby provides these Supplemental Disclosures to the Proxy Statement. This supplemental information should be read in conjunction with the Proxy Statement, which should be read in its entirety. Defined terms used but not defined below have the meanings set forth in the Proxy Statement.
1.       The section of the Proxy Statement entitled “Background to the Merger” is hereby supplemented as follows:

A.
The third full paragraph on page 34 (such paragraph beginning with “On October 20, 2023, Party A …”) of the Proxy Statement is hereby amended and restated to read as follows:

On October 20, 2023, Party A entered into a confidentiality and standstill agreement with Karuna, which included standstill provisions that fell away upon the announcement of the proposed transaction. Later that day, Karuna provided Party A and its representatives with access to certain non-public information in a virtual data room. On October 24, 2023, representatives of Party A met virtually with representatives of Karuna and its advisors for management meetings and due diligence discussions. Over the subsequent weeks, representatives of Party A and its outside advisors engaged in a due diligence review process to evaluate a potential transaction with Karuna, and representatives of Karuna continued to participate in due diligence calls and to make available certain non-public information in a virtual data room. At no time following the delivery by Party A of the Initial Party A Proposal, or otherwise in advance of the announcement of the transaction, did representatives of Party A or Bristol-Myers Squibb discuss with Mr. Meury or other representatives of Karuna potential employment or compensation arrangements for Mr. Meury or other members of Karuna’s senior management team following the consummation of a potential transaction.

B.
The third full paragraph on page 36 (such paragraph beginning with “On December 12, 2023, Mr. Meury …”) of the Proxy Statement is hereby amended and restated to read as follows:

On December 12, 2023, Mr. Meury met with Dr. Boerner. At this meeting, Dr. Boerner provided Mr. Meury with a verbal indication of interest for the acquisition of Karuna at a per share consideration consisting of $320.00 in cash plus a contingent value right instrument payable upon FDA approval of KarXT in Alzheimer’s Disease Psychosis by December 31, 2026 and assuming the KarXT label at such approval does not contain a Boxed Warning (the “Initial Bristol-Myers Squibb Proposal”). The consideration reflected in the proposal was in excess of the valuation represented by the Initial Party A Proposal. Dr. Boerner sent a letter memorializing these terms to Mr. Meury later that day.

C.
The sixth full paragraph on page 38 (such paragraph beginning with “Also on December 19, 2023, Dr. Boerner …”) of the Proxy Statement is hereby amended and restated to read as follows:

Also on December 19, 2023, Dr. Boerner notified Mr. Meury that Bristol-Myers Squibb reaffirmed its indication of interest to acquire Karuna for consideration of $320.00 per share in cash plus a contingent value right instrument, the term of which was extended from December 31, 2026 to March 30, 2027moderately (the “Revised Bristol-Myers Squibb Proposal”). Dr. Boerner also indicated that Bristol-Myers Squibb was prepared to enter into a transaction to acquire Karuna expeditiously. In addition, representatives of Covington submitted a markup of the draft merger agreement to representatives of Simpson Thacher.
2.       The section of the Proxy Statement entitled “Opinion of Karuna’s Financial Advisor” is hereby supplemented as follows:

A.
The last paragraph on page 49 under the heading “Illustrative Discounted Cash Flow Analysis” (such paragraph beginning with “Goldman Sachs derived ranges …”) of the Proxy Statement is hereby amended and restated to read as follows:

Goldman Sachs derived ranges of illustrative enterprise values for Karuna by adding the ranges of present values it derived above. Goldman Sachs then added from the range of illustrative enterprise values it derived for Karuna the amount of Karuna’s net cash of approximately $1.3 billion as of September 30, 2023, as provided by and approved for Goldman Sachs’ use by the management of Karuna to derive a range of illustrative equity values for Karuna. Goldman Sachs then divided the range of illustrative equity values it derived by the number of fully diluted outstanding shares of Karuna as of December 20, 2023, as, ranging from approximately 41.74 million to 42.05 million, calculated using the treasury stock method and data provided by and approved for Goldman Sachs’ use by the management of Karuna, using the treasury stock method, to derive a range of illustrative present values per share ranging from $213.89 to $257.33.

 B.
The first full paragraph on page 49 under the heading “Premia Paid Analysis” (such paragraph beginning with “Goldman Sachs reviewed and analyzed …”) of the Proxy Statement is hereby amended and restated to read as follows:

Goldman Sachs reviewed and analyzed, using publicly available information, the acquisition premia for acquisition transactions announced from January 1, 2018 through December 21, 2023 involving a public company in the biopharmaceutical industry as the target where the disclosed enterprise values for the transaction were between approximately $8 billion and $15 billion. The following table presents the results of this review:
Announcement Date
Selected Acquisition Transactions
Premium to Undisturbed
Stock Price
Acquiror
Target
December 6, 2023
AbbVie Inc.
Cerevel Therapeutics
Holdings, Inc.
73%
November 30, 2023
AbbVie Inc.
ImmunoGen, Inc.
95%
April 16, 2023
Merck & Co., Inc.
Prometheus Biosciences, Inc.
75%
May 10, 2022
Pfizer Inc.
Biohaven Pharmaceutical
Holding Company Ltd.
79%
September 30, 2021
Merck & Co., Inc.
Acceleron Pharma Inc.
36%
October 5, 2020
Bristol-Myers Squibb Company
MyoKardia, Inc.
61%
November 24, 2019
Novartis AG
The Medicines Company
45%
June 17, 2019
Pfizer Inc.
Array BioPharma Inc.
63%
April 9, 2018
Novartis AG
AveXis, Inc.
88%
January 22, 2018
Sanofi SA
Bioverativ Inc.
64%
January 22, 2018
Celgene Corporation
Juno Therapeutics, Inc.
91%

For the entire period, using publicly available information, Goldman Sachs calculated the median, mean, minimum, 25th percentile, 75th percentile and maximum premiums of the price paid in the 11 transactions relative to the target’s last undisturbed closing stock price prior to announcement of the respective transaction. This analysis indicated a median premium of 73%, mean premium of 70%, minimum premium of 36%, 25th percentile premium of 62%, 75th percentile premium of 84% and maximum premium of 95% across the period. Using this analysis, Goldman Sachs applied a reference range of illustrative premiums of 36% to 95% to the undisturbed closing price per share of Karuna common stock of $215.19 as of December 21, 2023 and calculated a range of implied equity values per share of Karuna common stock of $292.66 to $419.62.
3.       The section of the Proxy Statement entitled “Certain Financial Projections” is hereby supplemented as follows:

A.
The table on page 51 under the heading “Financial Projections (Risk-Adjusted) ($ in millions)” of the Proxy Statement is hereby amended and restated as follows:
 
   
Fiscal Year Ending December 31,
  
   
2023
    
2024
    
2025
    
2026
    
2027
    
2028
    
2029
    
2030
    
2031
  
Revenue
  
$
0
    
$
22
    
$
152
    
$
517
    
$
1,001
    
$
1,607
    
$
2,432
    
$
2,996
    
$
3,689
  
Gross Profit(1)
  
$
0
    
$
22
    
$
141
    
$
474
    
$
860
    
$
1,438
    
$
2,166
    
$
2,668
    
$
3,452
  
Net Operating Profit After Tax(2)
  
$ 
(294
)
  
$ 
(424
)
  
$ 
(300
)
  
$
21
    
$
299
    
$
669
    
$
1,042
    
$
1,334
    
$
1,804
  
Unlevered Free Cash Flow(3)
  
$ 
(299
)
  
$ 
(414
)
  
$ 
(306
)
  
$ 
(12
)
  
$
277
    
$
616
    
$
994
    
$
1,286
    
$
1,742
  
 
   
Fiscal Year Ending December 31,
  
   
2032
    
2033
    
2034
    
2035
    
2036
    
2037
    
2038
    
2039
    
2040
  
Revenue
  
$
4,419
    
$
5,086
    
$
5,725
    
$
6,329
    
$
6,950
    
$
7,520
    
$
8,070
    
$
6,865
    
$
2,794
  
Gross Profit
  
$
4,128
    
$
4,735
    
$
5,311
    
$
5,872
    
$
6,471
    
$
7,028
    
$
7,543
    
$
6,420
    
$
2,623
  
Net Operating Profit After Tax
  
$
2,212
    
$
2,577
    
$
2,919
    
$
3,250
    
$
3,593
    
$
3,927
    
$
4,227
    
$
3,549
    
$
1,298
  
Unlevered Free Cash Flow
  
$
2,150
    
$
2,509
    
$
2,849
    
$
3,182
    
$
3,525
    
$
3,877
    
$
4,172
    
$
3,554
    
$
1,274
  
 
   
Fiscal Year Ending December 31,
  
   
2041
    
2042
    
2043
    
2044
    
2045
    
2046
    
2047
    
2048
  
Revenue
  
$
2,532
    
$
2,501
    
$
2,547
    
$
2,552
    
$
2,567
    
$
2,050
    
$
1,506
    
$
1,315
  
Gross Profit
  
$
2,381
    
$
2,354
    
$
2,399
    
$
2,405
    
$
2,418
    
$
1,947
    
$
1,430
    
$
1,250
  
Net Operating Profit After Tax
  
$
1,155
    
$
1,137
    
$
1,160
    
$
1,160
    
$
1,165
    
$
923
    
$
655
    
$
561
  
Unlevered Free Cash Flow
  
$
1,128
    
$
1,109
    
$
1,137
    
$
1,151
    
$
1,159
    
$
920
    
$
654
    
$
560
  

  (1)
“Gross Profit” is a non-GAAP measure and refers to Karuna’s non-GAAP Risk-Adjusted Revenue less cost of goods sold.
  (2)
“Net Operating Profit After Tax” is a non-GAAP measure and refers to Karuna’s non-GAAP gross profit, less research and development expenses, less sales, general and administrative expenses, less tax.
  (3)
“Unlevered Free Cash Flow” is a non-GAAP measure and refers to non-GAAP Net Operating Profit After Tax, less capital expenditures and changes in net working capital, plus depreciation and amortization. Unlevered Free Cash Flow excludes free cash flow benefits from net operating losses.
 
  B.
The following paragraph is added on page 51 immediately following the table under the heading “Financial Projections (Risk-Adjusted)” of the Proxy Statement:

The Financial Projections were based on assumptions about Karuna’s continued operation as a stand-alone, publicly traded company, accounting for risk and probability adjustments reflecting Karuna senior management’s good faith assessment as to the probability of success on a product candidate by product candidate and indication by indication basis, accounting for the risks associated with preclinical development, each phase of clinical development, regulatory approval and potential sales thereof, most notably for the approval of KarXT for the treatment of schizophrenia, as of the time such Financial Projections were prepared. The Financial Projections include assumptions regarding Karuna’s worldwide commercialization of products as well as current and potential future partnerships, collaborations and licensing arrangements with third parties and royalties and milestone payments paid and received in connection with such collaborations. The Financial Projections were based on certain internal assumptions about the epidemiology, competition, market acceptance, pricing, reimbursement, patent protection, research and development expenses, sales and marketing expenses, general and administrative expenses, effective tax rate and utilization of net operating losses, future equity raises conducted by Karuna and other relevant factors related to Karuna’s long-range operating plan. The foregoing is a summary of certain key assumptions and does not purport to be a comprehensive or exhaustive overview of all metrics and assumptions include or reflected in the Financial Projections.
 
Forward-Looking Statements
This Form 8-K contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements are often identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “will,” “would” or the negative or plural of these words or similar expressions or variations. Forward-looking statements are made based upon management’s current expectations and beliefs and are not guarantees of future performance. Such forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by the forward-looking statements. These factors include, among others: completion of the proposed transaction being subject to various risks and uncertainties related to, among other things, its terms, timing, structure, benefits, costs and completion; required approvals to complete the proposed transaction by our stockholders and the receipt of certain regulatory approvals, to the extent required, and the timing and conditions for such approvals; the stock price of Karuna prior to the consummation of the proposed transaction; the satisfaction of the closing conditions to the proposed transaction; our limited operating history; our ability to obtain necessary funding; our ability to generate positive clinical trial results for our product candidates; risks inherent in clinical development; the timing and scope of regulatory approvals; changes in laws and regulations to which we are subject; competitive pressures; our ability to identify additional product candidates; risks relating to business interruptions; and other risks set forth under the heading “Risk Factors,” of our Annual Report on Form 10-K for the year ended December 31, 2023 and in our subsequent filings with the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. Furthermore, such forward-looking statements speak only as of the date of this report. Our actual results could differ materially from the results described in or implied by such forward looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements.
Additional Information and Where to Find It
This communication does not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities or a solicitation of any vote or approval. This communication relates to a proposed acquisition of Karuna by Bristol-Myers Squibb. In connection with this proposed acquisition, Karuna has filed one or more proxy statements or other documents with the SEC. This communication is not a substitute for the proxy statement or any other document that Karuna has filed with the SEC in connection with the proposed transaction. INVESTORS AND SECURITY HOLDERS OF KARUNA ARE URGED TO READ THE PROXY STATEMENT AND OTHER DOCUMENTS THAT HAVE BEEN AND MAY IN THE FUTURE BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION. The definitive proxy statement has been mailed to stockholders of Karuna. Investors and security holders are able to obtain free copies of these documents and other documents filed with the SEC by Karuna through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by Karuna are available free of charge on Karuna’s internet website at www.karunatx.com or upon written request to: Investor Relations, Karuna, 99 High Street, Floor 26, Boston, Massachusetts or by telephone at (857) 449-2244.
Participants in Solicitation
This communication does not constitute a solicitation of a proxy, an offer to purchase or a solicitation of an offer to sell any securities. Bristol Myers Squibb, Karuna and their respective directors, executive officers and certain employees may be deemed to be participants in the solicitation of proxies from the stockholders of Karuna in connection with the proposed acquisition. Information regarding Bristol Myers Squibb’s directors and executive officers is contained in Bristol Myer Squibb’s definitive proxy statement for the 2023 annual meeting of stockholders, which was filed with the SEC on March 23, 2023. Information regarding Karuna’s directors and executive officers is contained in Karuna’s definitive proxy statement for the 2023 annual meeting of stockholders, which was filed with the SEC on April 27, 2023. To the extent holdings of Bristol Myers Squibb’s or Karuna’s securities by their respective directors or executive officers have changed since the amounts set forth in such 2023 proxy statements, such changes have been or will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Beneficial Ownership on Form 4 filed with the SEC. Additional information regarding the identity of potential participants, and their direct or indirect interests, by security holdings or otherwise, is included in the Proxy Statement. These documents may be obtained free of charge from the SEC’s website at www.sec.gov, Bristol Myers Squibb’s website at www.bms.com and Karuna’s website at https://karunatx.com/.
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
KARUNA THERAPEUTICS, INC.
     
Date: March 1, 2024
By:
 /s/ Mia Kelley
   
Mia Kelley
   
General Counsel and Secretary


EX-101.SCH 2 krtx-20240301.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 krtx-20240301_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 4 krtx-20240301_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document and Entity Information
Mar. 01, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 01, 2024
Entity File Number 001-38958
Entity Registrant Name Karuna Therapeutics, Inc.
Entity Central Index Key 0001771917
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 27-0605902
Entity Address, Address Line One 99 High Street
Entity Address, Address Line Two Floor 26
Entity Address, City or Town Boston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02110
City Area Code 857
Local Phone Number 449-2244
Title of 12(b) Security Common stock, par value $0.0001
Trading Symbol KRTX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 23 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://karunatx.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports ef20022937_8k.htm krtx-20240301.xsd krtx-20240301_lab.xml krtx-20240301_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ef20022937_8k.htm": { "nsprefix": "krtx", "nsuri": "http://karunatx.com/20240301", "dts": { "inline": { "local": [ "ef20022937_8k.htm" ] }, "schema": { "local": [ "krtx-20240301.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "labelLink": { "local": [ "krtx-20240301_lab.xml" ] }, "presentationLink": { "local": [ "krtx-20240301_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 29, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://karunatx.com/role/DocumentAndEntityInformation", "longName": "000100 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c20240301to20240301", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20022937_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240301to20240301", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20022937_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://karunatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://karunatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://karunatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://karunatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://karunatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://karunatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://karunatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://karunatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://karunatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://karunatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://karunatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://karunatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://karunatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://karunatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://karunatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://karunatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://karunatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://karunatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://karunatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://karunatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://karunatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://karunatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://karunatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://karunatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://karunatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://karunatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://karunatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://karunatx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0001140361-24-010584-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-24-010584-xbrl.zip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ef20022937_8k_htm.xml IDEA: XBRL DOCUMENT 0001771917 2024-03-01 2024-03-01 false 0001771917 8-K 2024-03-01 Karuna Therapeutics, Inc. DE 001-38958 27-0605902 99 High Street Floor 26 Boston MA 02110 857 449-2244 false false false false Common stock, par value $0.0001 KRTX NASDAQ false